Evidence map›Paper›PMID 41229786›Full record

ArticleJournal of thoracic disease2025

The global, regional, and national burden of early, middle, and late-onset esophageal cancer and trends from 1990 to 2021: a systematic analysis of the Global Burden of Disease Study 2021.

Zongyuan Li, Jili Li, Cheng Yu, Jianqi Hao, Jiantong Sun, Yi Chen, Jian Zhang, Kejia Zhao, Feng Lin

Abstract read
In one paragraph

Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Zongyuan Li *Department of Thoracic Surgery and Institute of Thoracic Oncology, West China Hospital, Sichuan University, Chengdu, China.
Jili Li *Department of Thoracic Surgery and Institute of Thoracic Oncology, West China Hospital, Sichuan University, Chengdu, China.
Cheng YuDepartment of Thoracic Surgery and Institute of Thoracic Oncology, West China Hospital, Sichuan University, Chengdu, China.
Jianqi HaoDepartment of Thoracic Surgery and Institute of Thoracic Oncology, West China Hospital, Sichuan University, Chengdu, China.
Jiantong SunDepartment of Thoracic Surgery and Institute of Thoracic Oncology, West China Hospital, Sichuan University, Chengdu, China.
Yi ChenSchool of Clinical Medicine, Chengdu Medical College, Chengdu, China.
Jian ZhangDepartment of Thoracic Surgery and Institute of Thoracic Oncology, West China Hospital, Sichuan University, Chengdu, China.
Kejia ZhaoDepartment of Thoracic Surgery and Institute of Thoracic Oncology, West China Hospital, Sichuan University, Chengdu, China.
Feng LinDepartment of Thoracic Surgery and Institute of Thoracic Oncology, West China Hospital, Sichuan University, Chengdu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Although the overall burden has gradually decreased, our understanding of the differences in disease burden across various age groups remains incomplete and controversial. This study aimed to provide an updated estimate of the esophageal cancer burden, with a focus on temporal trends and age-specific patterns. Methods: We extracted data from the Global Burden of Disease Study (GBD) 2021. Esophageal cancer was grouped into three groups: early-onset (EOEC, 15-49 years), middle-onset (MOEC, 50-69 years), and late-onset esophageal cancer (LOEC, ≥70 years). Age-standardized rates (ASRs) ensured the comparability of age-standardized incidence rate (ASIR), mortality rate (ASMR), and disability-adjusted life-years (DALYs) rate (ASDR). Joinpoint regression identified temporal trends, and average annual percent change (AAPC) with 95% confidence intervals (CIs) was calculated. Furthermore, we conducted frontier, decomposition, cross-country inequality, and risk factor analyses. Bayesian age-period-cohort (BAPC) model was utilized to forecast future epidemiological trajectories from 2022 to 2035. Results: Globally, although the ASIR of EOEC declined from 1.95 per 100,000 in 1990 to 1.08 in 2021 with an AAPC of -1.9 (95% CI: -2.05 to -1.74, P<0.001), joinpoint regression analysis revealed that the ASIR of LOEC increased from 2014 to 2021. At regional levels, the highest ASRs of early, middle, and late-onset esophageal cancer were mainly observed in Sub-Saharan Africa and East Asia. Moreover, higher disease burden was found in lower sociodemographic index (SDI) countries. Smoking was the most important risk factor for esophageal cancer globally. Furthermore, the ASIR of EOEC and LOEC were projected to increase worldwide from 2022 to 2035. Conclusions: Our findings highlighted the need for targeted cancer control strategies that address population-specific needs, particularly with respect to age, gender, and sociodemographic disparities.

Indexed as

Esophageal cancerGlobal Burden of Disease (GBD)incidencemortalitypublic health

Identifiers

PMID41229786
PMCPMC12603433

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.